Alnylam Pharmaceuticals, Elan, NeuroPhage Pharmaceuticals and Prana Biotechnology are among the drugmakers developing therapies that focus on reducing alpha-synuclein in the brains of Parkinson's disease patients, but new research associates low levels of the protein with worsening symptoms. Parkinson's patients who had the lowest production of alpha-synuclein had a 23% higher risk of developing dementia or becoming disabled than patients with the highest levels, researchers reported at an American Academy of Neurology meeting.
Parkinson's researchers might be chasing the wrong culprit
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||